Proximal tibial valgus osteotomy. The Veterans Administration Hospital experience, Wichita, Kansas, 1977-82.

M. Bernhardt,Plaster Rl,M. Ho

1987-09-01

Abstract:

What problem does this paper attempt to address?

Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

Toshihiro Takahashi,Tomohiko Ai,Kaori Saito,Shuko Nojiri,Maika Takahashi,Gene Igawa,Takamasa Yamamoto,Abdullah Khasawneh,Faith Jessica Paran,Satomi Takei,Yuki Horiuchi,Takayuki Kanno,Minoru Tobiume,Makoto Hiki,Mitsuru Wakita,Takashi Miida,Atsushi Okuzawa,Tadaki Suzuki,Kazuhisa Takahashi,Toshio Naito,Yoko Tabe

DOI: https://doi.org/10.1371/journal.pone.0291670

IF: 3.7

2023-09-20

PLoS ONE

Abstract:The COVID-19 antibody test was developed to investigate the humoral immune response to SARS-CoV-2 infection. In this study, we examined whether S antibody titers measured using the anti-SARS-CoV-2 IgG II Quant assay (S-IgG), a high-throughput test method, reflects the neutralizing capacity acquired after SARS-CoV-2 infection or vaccination. To assess the antibody dynamics and neutralizing potency, we utilized a total of 457 serum samples from 253 individuals: 325 samples from 128 COVID-19 patients including 136 samples from 29 severe/critical cases (Group S), 155 samples from 71 mild/moderate cases (Group M), and 132 samples from 132 health care workers (HCWs) who have received 2 doses of the BNT162b2 vaccinations. The authentic virus neutralization assay, the surrogate virus neutralizing antibody test (sVNT), and the Anti-N SARS-CoV-2 IgG assay (N-IgG) have been performed along with the S-IgG. The S-IgG correlated well with the neutralizing activity detected by the authentic virus neutralization assay (0.8904. of Spearman's rho value, p < 0.0001) and sVNT (0.9206. of Spearman's rho value, p < 0.0001). However, 4 samples (2.3%) of S-IgG and 8 samples (4.5%) of sVNT were inconsistent with negative results for neutralizing activity of the authentic virus neutralization assay. The kinetics of the SARS-CoV-2 neutralizing antibodies and anti-S IgG in severe cases were faster than the mild cases. All the HCWs elicited anti-S IgG titer after the second vaccination. However, the HCWs with history of COVID-19 or positive N-IgG elicited higher anti-S IgG titers than those who did not have it previously. Furthermore, it is difficult to predict the risk of breakthrough infection from anti-S IgG or sVNT antibody titers in HCWs after the second vaccination. Our data shows that the use of anti-S IgG titers as direct quantitative markers of neutralizing capacity is limited. Thus, antibody tests should be carefully interpreted when used as serological markers for diagnosis, treatment, and prophylaxis of COVID-19.

multidisciplinary sciences
Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Danrong Shi,Tianhao Weng,Jie Wu,Chunyan Dai,Rui Luo,Keda Chen,Miaojin Zhu,Xiangyun Lu,Linfang Cheng,Qiuqiang Chen,Fumin Liu,Zhigang Wu,Haibo Wu,Changzhong Jin,Miao Guo,Zhe Chen,Nanping Wu,Hangping Yao,Min Zheng

DOI: https://doi.org/10.3389/fimmu.2021.708184

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:There is a worldwide pandemic of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; yet our understanding remains limited on the characteristic of antibodies, especially for dynamic long-term tracking. Sequential serum samples were collected up to 416 days post onset of symptoms (POS) from 102 patients who were hospitalized with coronavirus disease 2019 (COVID-19). Immunoglobulin (Ig)G, IgM, and IgA levels targeting SARS-CoV-2 spike 1 receptor-binding domain (S1-RBD), spike 2 extracellular domain (S2-ECD), and nucleocapsid protein (N) were quantified as well as neutralizing activity. We were pleasantly surprised to find that the antibody remained detective and effective for more than a year POS. We also found the varied reactions of different antibodies as time passed: N-IgA rose most rapidly in the early stage of infection, while S2-IgG was present at a high level in the long time of observation. This study described the long traceable antibody response of the COVID-19 and offered hints about targets to screen for postinfectious immunity and for vaccination development of SARS-CoV-2.
Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits

Yan Yan,Kaori Saito,Toshio Naito,Kanami Ito,Shuko Nojiri,Yuki Horiuchi,Gautam A. Deshpande,Hirohide Yokokawa,Yoko Tabe

DOI: https://doi.org/10.1038/s41598-024-53656-2

IF: 4.6

2024-02-08

Scientific Reports

Abstract:Antibody tests are used as surveillance tools for informing health policy making. However, results may vary by type of antibody assay and timing of sample collection following infection. Long-term longitudinal cohort studies on antibody assay seropositivity have remained limited, especially among Asian populations. Using blood samples obtained at health physicals (2020–2022) of healthcare workers (mass vaccinated with mRNA COVID-19 vaccines) at a Japanese medical center, we measured N-specific antibodies using two commercially available systems. Roche Elecsys Anti-SARS-CoV-2 measures total antibodies and Abbott Alinity SARS-CoV-2 IgG measures only IgG. Among 2538 participants, seroprevalence was found to be 16.6% via total antibody assay versus 12.9% by IgG-only (including grayzone) by mid-June 2022. For 219 cases with a previous PCR-confirmed infection, positivity was 97.3% using total antibody assay versus 76.3% using IgG-only assay at the 2022 health physical. Using PCR positive test date as day 0, while the positivity of the total antibody assay was retained for the entire study period (until more than 24-months post-infection), the IgG-only assay's positivity declined after month 4. The Mantel–Haenszel test found a significant difference in the two assays' seropositivity, between stratified groups of "within 3 months" and "4 months or more" from infection ( P < 0.001). Our study found significant differences in seropositivity over time of total antibody versus IgG-only assays, suggesting an optimal assay for retaining sensitivity over the entire infection period when designing seroprevalence studies.

multidisciplinary sciences
Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies

Melvin E Klegerman,Tao Peng,Ira Seferovich,Mohammad H Rahbar,Manouchehr Hessabi,Amirali Tahanan,Audrey Wanger,Carolyn Z Grimes,Luis Z Ostrosky-Zeichner,Kent Koster,Jeffrey D Cirillo,Dinuka Abeydeera,Steve De Lira,David D McPherson

DOI: https://doi.org/10.1371/journal.pone.0311777

IF: 3.7

2024-11-01

PLoS ONE

Abstract:Soon after commencement of the SARS-CoV-2 disease outbreak of 2019 (COVID-19), it became evident that the receptor-binding domain of the viral spike protein is the target of neutralizing antibodies that comprise a critical element of protective immunity to the virus. This study addresses the relative lack of information regarding actual antibody concentrations and binding affinities in convalescent plasma (CP) samples from COVID-19 patients and extends these analyses to post-vaccination (PV) samples to estimate protective IgG antibody (Ab) levels. A direct enzyme-linked immunosorbent assay (ELISA) was used to measure IgG anti-spike protein (SP) antibodies (Abs) relative to human chimeric spike S1 Ab standards. Microplate wells were coated with recombinant SP. Affinities of Ab binding to SP were determined by previously described methods. Binding affinities were also determined in an RBD-specific sandwich ELISA. Two indices of protective immunity were determined as permutations of Ab molar concentration divided by affinity as dissociation constant (KD). The range and geometric means of Ab concentrations in 21 CP and 21 PV samples were similar and a protective Ab level of 7.5 μg/ml was determined for the latter population, based on 95% of the normal distribution of the PV population. A population (n = 21) of plasma samples from individuals receiving only one vaccination with the BNT162b2 or mRNA-1273 vaccines (PtV) exhibited a geometric mean Ab concentration significantly (p < 0.03) lower than the PV population. The results of this study have implications for future vaccine development, projection of protective efficacy duration, and understanding of the immune response to SARS-CoV-2 infection.
Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay

Chang Zhou,Ge Bu,Yong Sun,Cuiping Ren,Mingsheng Qu,Yufeng Gao,Yulin Zhu,Linding Wang,Liang Sun,Yan Liu

DOI: https://doi.org/10.1002/jmv.26741

IF: 20.693

2021-03-01

Journal of Medical Virology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>SARS‐CoV‐2 is sweeping the world since the end of 2019. The titer change of antibodies against SARS‐CoV‐2 needs to be further clarified, the clinical and preventive value of antibodies still needs to be further investigated.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Method</h3><p>An ELISA was established by coating with SARS‐CoV‐2 recombinant spike protein and used to detect serum IgM and IgG antibodies against SARS‐CoV‐2 in COVID‐19 patients to evaluate the pattern of changes of antibodies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The specificity of the ELISA for detection SARS‐CoV‐2 IgM and IgG were 96% (144/150) and 100% (150/150), respectively. The sensitivity of ELISA was 100% (150/150) for IgM, and 99.3% (149/150) for IgG. SARS‐CoV‐2‐SP‐IgM and SP‐IgG antibodies could be detected on day 1 of hospitalization in 12.5% patients, and SP‐IgM began to decrease after reaching its peak at around 22‐28 days, and become negative at month 3 in 30% patients and negative at month 7 in 79% of these patients after onset; IgG reached its peak around day 22‐28 and kept at a high level within the longest observation period for 4 months, it dropped very sharply at 7 months. The positive rates of SP‐IgM and SP‐IgG were higher than those of RT‐qPCR on day 7 and 4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The established indirect ELISA has good specificity and sensitivity. IgM and IgG against SARS‐CoV‐2 appeared almost simultaneously in the early stage, and the level of IgG antibodies couldn't maintain a high plateau in the observation period of 7 months. Our data will help develop the diagnosis and vaccine of SARS‐CoV‐2.</p><p>This article is protected by copyright. All rights reserved.</p></section>

virology
Antibody titers and the risk of infection during the SARS-CoV-2 Omicron phase in Bizen City, Japan

Tomoka Kadowaki,Ayako Sasaki,Naomi Matsumoto,Toshiharu Mitsuhashi,Hideharu Hagiya,Soshi Takao,Takashi Yorifuji

DOI: https://doi.org/10.1093/infdis/jiae207

2024-04-25

The Journal of Infectious Diseases

Abstract:Understanding the association between the immune response and the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has implications for forthcoming prevention strategies. We evaluated the association between antibody titers and the risk of infection for the general population during the Omicron-dominant phase. This was a prospective cohort study of residents or people affiliated with institutions in Bizen City, which included 1,899 participants. We measured the titers of antibodies against SARS-CoV-2 repeatedly every 2 months from June 2022 to March 2023. Infection status was obtained from self-reported questionnaires and the official registry. We estimated risk ratios (RRs) for infection within 2 months of the date of each antibody measurement with 95% confidence intervals (CIs) based on antibody titer categories and spline functions. Compared with the <2,500 arbitrary unit (AU)/mL category, the 2,500–5,000, 5,000–10,000, and ≥10,000 AU/mL categories had adjusted RRs (95% CI) of 0.81 (0.61–1.08), 0.51 (0.36–0.72), and 0.41 (0.31–0.54), respectively. The spline function showed a non-linear relationship between antibody titer and risk. Higher antibody titers were associated with a lower risk. We demonstrate the usefulness of measuring an antibody titers to determine the appropriate timing for future vaccination.

immunology,infectious diseases,microbiology
Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort

Shihan Zhang,Ke Xu,Chuchu Li,Lu Zhou,Xiaoxiao Kong,Jiefu Peng,Fengcai Zhu,Changjun Bao,Hui Jin,Qiang Gao,Xing Zhao,Liguo Zhu

DOI: https://doi.org/10.3389/fimmu.2022.829665

IF: 7.3

2022-01-27

Frontiers in Immunology

Abstract:Background Understanding the long-term kinetic characteristics of SARS-CoV-2 antibodies and the impact of inactivated vaccines on SARS-CoV-2 antibodies in convalescent patients can provide information for developing and improving vaccination strategies in such populations. Methods In this cohort, 402 convalescent patients who tested positive for SARS-CoV-2 by RT-PCR from 1 January to 22 June 2020 in Jiangsu, China, were enrolled. The epidemiological data included demographics, symptom onset, and vaccination history. Blood samples were collected and tested for antibody levels of specific IgG, IgM, RBD-IgG, S-IgG, and neutralizing antibodies using a the commercial magnetic chemiluminescence enzyme immunoassay. Results The median follow-up time after symptom onset was 15.6 months (IQR, 14.6 to 15.8). Of the 402 convalescent patients, 44 (13.84%) received an inactivated vaccine against COVID-19. A total of 255 (80.19%) patients were IgG-positive and 65 (20.44%) were IgM-positive. The neutralizing antibody was 83.02%. Compared with non-vaccinated individuals, the IgG antibody levels in vaccinated people were higher (P=0.007). Similarly, antibody levels for RBD-IgG, S-IgG, and neutralizing antibodies were all highly increased in vaccinated individuals (P<0.05). IgG levels were significantly higher after vaccination than before vaccination in the same population. IgG levels in those who received ‘single dose and ≥14d’ were similar to those with two doses (P>0.05). Similar conclusions were drawn for RBD-IgG and the neutralizing antibody. Conclusion 15.6 months after symptom onset, the majority of participants remained positive for serum-specific IgG, RBD-IgG, S-IgG, and neutralizing antibodies. For convalescent patients, a single dose of inactivated vaccine against COVID-19 can further boost antibody titres.

immunology
Quantitative Detection of Anti-SARS-CoV-2 Antibodies Using Indirect ELISA

Shuhong Luo,Jianhua Xu,Chih Yun Cho,Siwei Zhu,Kelly C Whittaker,Xingqi Wang,Jie Feng,Meng Wang,Shehuo Xie,Jianmin Fang,Andy S Huang,Xuedong Song,Ruo-Pan Huang

DOI: https://doi.org/10.1093/labmed/lmab085

IF: 1.865

2021-10-27

Laboratory Medicine

Abstract:Abstract Objective Real-time reverse transcription-polymerase chain reaction is the gold standard for the diagnosis of COVID-19, but it is necessary to utilize other tests to determine the burden of the disease and the spread of the outbreak such as IgG-, IgM-, and IgA-based antibody detection using enzyme-linked immunosorbent assay (ELISA). Materials and Methods We developed an indirect ELISA assay to quantitatively measure the amount of COVID-19 IgG, IgM, and IgA antibodies present in patient serum, dried blood, and plasma. Results The population cutoff values for positivity were determined by receiver operating characteristic curves to be 1.23 U/mL, 23.09 U/mL, and 6.36 U/mL for IgG, IgM, and IgA, respectively. After albumin subtraction, the specificity remained >98% and the sensitivity was 95.72%, 83.47%, and 82.60%, respectively, for IgG, IgM, and IgA antibodies to the combined spike subunit 1 receptor binding domain and N proteins in serum. Plasma and dried blood spot specimens were also validated on this assay. Conclusion This assay may be used for determining the seroprevalence of SARS-CoV-2 in a population exposed to the virus or in vaccinated individuals.

medical laboratory technology
Rapid and Low-Cost Detection and Quantification of SARS-CoV-2 Antibody Titers of ICU Patients with Respiratory Deterioration Using a Handheld Thermo-Photonic Device

Damber Thapa,Nakisa Samadi,Andrew Baker,Claudia Dos Santos,Uriel Trahtemberg,Nima Tabatabaei

DOI: https://doi.org/10.3390/biomedicines10061424

IF: 4.757

2022-06-15

Biomedicines

Abstract:While research suggests that COVID-19 vaccines are effective in producing anti-SARS-CoV-2 antibodies that reduce the risk of COVID-19 and its potentially severe complications, how long these antibodies persist after the infection/vaccination is unknown. Longitudinal studies and rapid and scalable platforms are needed for large-scale sero-diagnosis and vaccine evaluation. In this study, we examine the efficacy of our recently-developed handheld thermo-photonic device for rapid and low-cost assessment of the adaptive immune response of COVID+ and COVID- patients admitted to the intensive care unit (ICU) at a local hospital due to respiratory deterioration. Antibody testing included detection and quantification of IgG and IgM via thermo-photonic sensing of a commercially available COVID-19 IgG/IgM rapid test as well as standard measurements with quantitative enzyme-linked immunosorbent assays (qELISA). The results demonstrate that the thermo-photonic reader in conjunction with COVID-19 IgG/IgM test cassettes can detect and quantify IgG levels in COVID-19 antibody assays within the clinically relevant range and with a high correlation to those obtained from qELISA. We also found that the IgG antibody is more reliable for detecting individuals with an adaptive immune response to SARS-CoV-2 compared to the IgM antibody. The developed reader offers a low-cost, portable, and scalable solution for accessing the antibody titer of individuals against SARS-CoV-2 and can be used in local hospital settings.
Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status

Sally A. Mahmoud,Subhashini Ganesan,Shivaraj Naik,Safaa Bissar,Isra Zamil,Walid Abbas Zaher

DOI: https://doi.org/10.1101/2021.04.27.21256205

2021-04-30

Abstract:Abstract Background The anti-SARS-CoV-2 immunological assays have promising applications in the control and surveillance of the current COVID-19 pandemic. Therefore, large number of serological assays are developed in the commercial market to measure SARS-CoV-2 antibodies, which requires evaluation before their application in large scale. Objectives To evaluate the performances of commercially available serological assays for detecting SARS-CoV-2 antibodies. Methods The study compared the performances of six different methods for detection of antibodies against SARS-CoV-2 which includes (i) Genscript SARS-CoV-2 surrogate virus neutralization test kit [Test A] (ii) Diasorin - SARS-CoV-2 S1/S2 IgG detection [Test B] (iii) Alinity SARS-CoV-2 IgG II [Test C] (iv) Diasorin – SARS-CoV-2 TrimericS IgG [Test D] (v) Roche Elecsys Anti-SARS-CoV-2 – cobas [Test E] (vi) AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction Neutralization Test (PRNT). Results Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A, C, D and E showed optimum cut-offs that differed from the manufacturer’s recommendation. Test D had the best performance considering all the performance indicators with the highest agreement with the PRNT results. Parallel testing of test A with test D and test B had the optimum performance. Conclusion Serological assays that are commercially available are very promising and show good agreement with the standard PRNT results. Studies on large samples for optimization of the assay cut-off values and cost-effective evaluations on parallel testing methods are needed to make recommendations on these commercial assays. Importance Serological assays that are commercially available are very promising and this paper adds new knowledge about the optimization of these kits for evaluating post vaccination antibodies status. It highlights the positive and negative aspects of each of these assays in terms of sensitivity, specificity, positive and negative predictive values, and the agreement of results with the standard neutralization test. When serological assays are being used to assess post-vaccine immune status, a balance of all parameters needs to be considered rather than emphasizing only on high specificity. This is particularly relevant in the current situation where vaccination is happening around the globe, high sensitivity assays will result in reporting a lower percentage of false negative reports and avoids panic about lack of vaccine response. It is important that we understand the strengths and limitations of commercially available serological assays for better application of these tests to understand immune response and the duration of protection post vaccination.
Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications

Marinos C. Dalakas,Kleopatra Bitzogli,Harry Alexopoulos

DOI: https://doi.org/10.3389/fimmu.2021.627285

IF: 7.3

2021-02-17

Frontiers in Immunology

Abstract:Introduction: Cross-reactivity to SARS-CoV-2 antigenic peptides has been detected on T-cells from pre-pandemic donors due to recognition of conserved protein fragments within members of the coronavirus's family. Further, preexisting antibodies recognizing SARS-CoV-2 with conserved epitopes in the spike region have been now seen in uninfected individuals. High-dose Intravenous Immunoglobulin (IVIg), derived from thousands of healthy donors, contains natural IgG antibodies against various antigens which can be detected both within the IVIg preparations and in the serum of IVIg-receiving patients. Whether IVIg preparations from pre-pandemic donors also contain antibodies against pre-pandemic coronaviruses or autoreactive antibodies that cross-react with SARS-CoV-2 antigenic epitopes, is unknown. Methods: 13 samples from 5 commercial IVIg preparations from pre-pandemic donors (HyQvia (Baxalta Innovations GmbH); Privigen (CSL Behring); Intratect (Biotest AG); IgVena (Kedrion S.p.A); and Flebogamma (Grifols S.A.) were blindly screened using a semi-quantitative FDA-approved and validated enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lubeck, Germany). Results: Nine of thirteen preparations (69.2%), all from two different manufactures, were antibody-positive based on the defined cut-off positivity (index of sample OD to calibrator OD > 1.1). From one manufacturer, 7/7 lots (100%) and from another 2/3 lots (67%), tested positive for cross-reacting antibodies. 7/9 of the positive preparations (77%) had titers as seen in asymptomatically infected individuals or recent COVID19-recovered patients, while 2/9 (23%) had higher titers, comparable to those seen in patients with active symptomatic COVID-19 infection (index > 2.2). Conclusion: Pre-pandemic IVIg donors have either natural autoantibodies or pre-pandemic cross-reactive antibodies against antigenic protein fragments conserved among the “common cold” - related coronaviruses. The findings are important in: (a) assessing true anti-SARS-CoV-2-IgG seroprevalence avoiding false positivity in IVIg-receiving patients; (b) exploring potential protective benefits in patients with immune-mediated conditions and immunodeficiencies receiving acute or chronic maintenance IVIg therapy, and (c) validating data from a recent controlled study that showed significantly lower in-hospital mortality in the IVIg- treated group.

immunology
Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2

Serge Ouoba,Aya Sugiyama,Ko Ko,Ulugbek Khudayberdievich Mirzaev,Kanon Abe,Bunthen E,Zayar Phyo,Kobiljon Khusniddin Khalilov,Akemi Kurisu,Tomoyuki Akita,Kazuaki Takahashi,Hiroshi Sasaki,Takumi Yamamoto,Junko Tanaka

DOI: https://doi.org/10.1002/jmv.29826

Abstract:Commercially available assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) or anti-nucleocapsid (N) antibodies differ in units, making results comparisons challenging. This study aimed to develop conversion equations between five quantitative anti-S antibody tests and to assess the agreement over time between three qualitative anti-N antibody tests. Blood samples from 24 216 vaccinated healthcare workers in Hiroshima Prefecture, Japan, were analyzed for anti-S antibodies using five quantitative tests (Abbott, Fujirebio, Ortho, Sysmex, Roche) and for anti-N antibodies using three qualitative tests (Abbott, Sysmex, Roche). Geometric mean regression was performed to establish equations for converting measured values between the five quantitative tests. Fleiss κ statistic was used to assess the agreement between the three qualitative tests. A strong correlation (Pearson's coefficient r > 0.9) was found for each pair of the five quantitative tests measuring anti-S antibodies, enabling the development of equations to convert values between each pair. Using these equations, which are based on the original output unit of each test, values obtained from one test can be transformed to be equivalent to the corresponding values in another test. For the three tests for anti-N antibodies, the agreement was substantial in the total sample (Fleiss' κ, 0.74) and moderate among those with self-reported past coronavirus disease 2019 (COVID-19) infection (Fleiss' κ, 0.39). The agreement decreased with time after infection. Reduced agreement between anti-N antibodies tests over time suggests caution in comparing seroepidemiological studies of COVID-19 exposure based on anti-N antibodies measurement. The findings could help improve antibody measurement systems and inform public health decision-makers.
Validation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2

Yunhwa Kim,Eun-Jeong Jang,Ji-Young Hwang,Kyung-Min Lee,Sivilay Xayaheuang,Seok-Tae Choi,Hosun Park

DOI: https://doi.org/10.1080/21645515.2024.2428516

2024-11-30

Human Vaccines & Immunotherapeutics

Abstract:The COVID-19 pandemic forced the rapid development of methods to measure humoral and cellular immunity against SARS-CoV-2. The lack of a global standardized protocol and the high variability of intra- and inter-assay precision of the T-cell response made it difficult to compare T-cell assay results with those of other laboratories. The interferon-gamma enzyme-linked immunosorbent spot (IFN-γ ELISpot) assay for immunogenicity evaluation was validated using naturally infected donor peripheral blood mononuclear cells, a commercially available IFN-γ ELISpot kit, and a SARS-CoV-2 specific peptide pool. Depending on anti-CD3 and peptide pool stimulation, the mean coefficients of variation (CVs) of the intra-assay precision were 19.0% and 13.4%, respectively. The mean CVs of the inter-assay precision were 26.1% and 25.4%, and the mean CVs for reproducibility were 6.7% and 15.9%, respectively. Linearity with an R-squared value between 0.98 and 0.99 was established, and the mean CVs between the lots were 17.6% and 6.6%, depending on the anti-CD3 and peptide pool stimulation, respectively. The limit of detection was 11 spot-forming counts per well. Taken together, we demonstrated that the IFN-γ ELISpot assay is feasible for evaluating SARS-CoV-2-specific cell-mediated immune function through validation based on standard operating procedures.

immunology,biotechnology & applied microbiology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study

Alexandra Cann,Candice Clarke,Jonathan Brown,Tina Thomson,Maria Prendecki,Maya Moshe,Anjna Badhan,Bryony Simmons,Bob Klaber,Paul Elliott,Ara Darzi,Steven Riley,Deborah Ashby,Paul Martin,Sarah Gleeson,Michelle Willicombe,Peter Kelleher,Helen Ward,Wendy S. Barclay,Graham S. Cooke

DOI: https://doi.org/10.12688/wellcomeopenres.17231.2

2022-05-26

Wellcome Open Research

Abstract:Background: Lateral flow immunoassays (LFIAs) are able to achieve affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Methods: This was a prospective diagnostic accuracy study. Sampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Two cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following two doses of SARS-CoV-2 vaccine, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination and subsequent follow up. During the participants visit, finger-prick blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG was detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA. A total of 186 paired samples were collected. The accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay Results: The LFIA had an estimated sensitivity of 92.0% (114/124; 95% confidence interval [CI] 85.7% to 96.1%) and specificity of 93.6% (58/62; 95% CI 84.3% to 98.2%) using the Abbott assay as reference standard (using the threshold for positivity of 7.10 BAU/ml) Conclusions: Fortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveillance but does not meet criteria for individual testing.
Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation

Jing Ma,Zhangkai J. Cheng,Mingshan Xue,Huimin Huang,Shiyun Li,Yanting Fang,Yifeng Zeng,Runpei Lin,Zhiman Liang,Huan Liang,Yijun Deng,Yuanyi Cheng,Shuangshuang Huang,Qian Wang,Xuefeng Niu,Siping Li,Peiyan Zheng,Baoqing Sun

DOI: https://doi.org/10.3389/fimmu.2022.913732

IF: 7.3

2022-06-23

Frontiers in Immunology

Abstract:Levels of neutralizing antibodies (NAb) after vaccine against coronavirus disease 2019 (COVID-19) can be detected using a variety of methods. A critical challenge is how to apply simple and accurate methods to assess vaccine effect. In a population inoculated with three doses of the inactivated Sinopharm/BBIBP vaccine, we assessed the performance of chemiluminescent immunoassay (CLIA) in its implementation to detect severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies, as well as the antibody kinetics of healthcare workers throughout the course of vaccination. The antibody levels of NAb, the receptor-binding-domain (RBD) antibodies and IgG peaked one month after the second and remained at a relatively high level for over three months after the booster injection, while IgM and IgA levels remained consistently low throughout the course of vaccination. The production of high-level neutralizing antibodies is more likely when the inoculation interval between the first two doses is within the range of one to two months, and that between the first and booster dose is within 230 days. CLIA showed excellent consistency and correlation between NAb, RBD, and IgG antibodies with the cytopathic effect (CPE) conventional virus neutralization test (VNT). Receiver operating characteristic (ROC) analysis revealed that the optimal cut-off levels of NAb, RBD and IgG were 61.77 AU/ml, 37.86 AU/ml and 4.64 AU/ml, with sensitivity of 0.833, 0.796 and 0.944, and specificity of 0.768, 0.750 and 0.625, respectively, which can be utilized as reliable indicators of COVID-19 vaccination immunity detection.

immunology
Performance Analysis of Serodiagnostic Tests to Characterize the Incline and Decline of the Individual Humoral Immune Response in COVID-19 Patients: Impact on Diagnostic Management

Ronald von Possel,Babett Menge,Christina Deschermeier,Carlos Fritzsche,Christoph Hemmer,Hilte Geerdes-Fenge,Micha Loebermann,Anette Schulz,Erik Lattwein,Katja Steinhagen,Ralf Tönnies,Reiner Ahrendt,Petra Emmerich

DOI: https://doi.org/10.3390/v16010091

2024-01-07

Viruses

Abstract:Serodiagnostic tests for antibody detection to estimate the immunoprotective status regarding SARS-CoV-2 support diagnostic management. This study aimed to investigate the performance of serological assays for COVID-19 and elaborate on test-specific characteristics. Sequential samples (n = 636) of four panels (acute COVID-19, convalescent COVID-19 (partly vaccinated post-infection), pre-pandemic, and cross-reactive) were tested for IgG by indirect immunofluorescence test (IIFT) and EUROIMMUN EUROLINE Anti-SARS-CoV-2 Profile (IgG). Neutralizing antibodies were determined by a virus neutralization test (VNT) and two surrogate neutralization tests (sVNT, GenScript cPass, and EUROIMMUN SARS-CoV-2 NeutraLISA). Analysis of the acute and convalescent panels revealed high positive (78.3% and 91.6%) and negative (91.6%) agreement between IIFT and Profile IgG. The sVNTs revealed differences in their positive (cPass: 89.4% and 97.0%, NeutraLISA: 71.5% and 72.1%) and negative agreement with VNT (cPass: 92.3% and 50.0%, NeutraLISA: 95.1% and 92.5%) at a diagnostic specificity of 100% for all tests. The cPass showed higher inhibition rates than NeutraLISA at VNT titers below 1:640. Cross-reactivities were only found by cPass (57.1%). Serodiagnostic tests, which showed substantial agreement and fast runtime, could provide alternatives for cell-based assays. The findings of this study suggest that careful interpretation of serodiagnostic results obtained at different times after SARS-CoV-2 antigen exposure is crucial to support decision-making in diagnostic management.

virology
In-network processing of the GPU-based real-time DXT compression

N. Kim,Jae-Yong Yoo,N. Kim,JongWon Kim

DOI: https://doi.org/10.1145/2079327.2079351

2011-12-06

Abstract:In this paper, we show our on-going work on realizing a PC-based network switch that provides low-latency in-network processing of GPU-based DXT compression.
Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations

Caiqin Hu,Dan Li,Zhanmou Liu,Li Ren,Junwei Su,Meiling Zhu,Yi Feng,Zheng Wang,Qiang Liu,Biao Zhu,Yiming Shao

DOI: https://doi.org/10.3390/pathogens11020171

IF: 3.7

2022-01-27

Pathogens

Abstract:Assessing the duration of neutralizing antibodies (nAbs) following SARS-CoV-2 infection or vaccination is critical to evaluate the protective immunity and formulate public health strategies. In this study, SARS-CoV-2 Ab ELISA (enzyme-linked immunosorbent assay), chemiluminescent microparticle immunoassay (CMIA), as well as pseudovirus neutralization test (PVNT) were performed in two cohorts, convalescent patients (CP) from coronavirus disease 2019 (COVID-19) and BBIBP-CorV vaccinated population. It was found that nAbs and binding antibodies emerged at 14 days post the 1st dose of vaccination, reached peaks at 28 days after 2nd dose vaccination and then gradually declined over time. CP-6M (convalescent patients up to 6 months) from COVID-19 presented stronger nAbs or binding antibodies responses than vaccinees 90 days or 180 days after 2nd dose vaccination. CMIA or SARS-CoV-2 Ab ELISA correlated well with PVNT with high consistency in the two cohorts. It shown that nAbs and binding antibodies can keep 6 months both in CP and vaccinees. Most importantly, our data show the application of using CMIA and SARS-CoV-2 Ab ELISA as rapid screening tests for nAb titer and could be used as alternative strategies for quickly evaluating SARS-CoV-2 nAbs responses in vaccine research.

microbiology
Study of the humoral immune response against SARS-CoV-2 post-infectious and post-vaccination

Fatima zahra,S.,Mamouzi,S.,Zerouki,A.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5317

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:COVID-19 remains an emerging disease that continues to challenge our immuno virological knowledge Thus, to better understand the pathophysiology of the infection it seemed urgent to us to define the place of serological tests and immunological investigations in the medium and long term monitoring of patients, in particular the monitoring of cohorts of infected and vaccinated subjects. Our study included 509 patients of different sexes with 206 patients infected with SARS-CoV-2,254 patients vaccinated against SARS-CoV-2(sputnik=169, sinovac=85)and 49 patients (hybrid group) at the both vaccinated and infected. The clinical signs mainly found in infected and infected vaccinated patients are asthenia, fever, dry cough, headaches, anosmia, ageusia with mainly benign forms. The most frequently observed adverse reactions in vaccinated patients and the hybrid group are:asthenia, fever, body aches, chills, headache and pain at the injection site. The majority of infected and vaccinated patients had a high viral load, and the most frequent comorbidities in the three groups are hypertension, diabetes, asthma. Analysis of the kinetics of anti-SARS-CoV-2 antibodies shows that infected and vaccinated patients have higher antibody levels than those in other groups. In addition, these antibody levels are maintained high until the 9th month while these kinetics decrease from the 3rd month in the group infected or vaccinated alone. Our data show that anti-SARS-CoV-2 antibody responses persist for at least 3 months after symptom onset and that IgG levels remain relatively stable during the post-convalescence period in COVID-19 patients.

respiratory system
The early detection of immunoglobulins via optical-based lateral flow immunoassay platform in COVID-19 pandemic

Pang-Yen Chen,Cheng-Hao Ko,C. Jason Wang,Chien-Wei Chen,Wei-Huai Chiu,Chitsung Hong,Hao-Min Cheng,I-Jen Wang

DOI: https://doi.org/10.1371/journal.pone.0254486

IF: 3.7

2021-07-20

PLoS ONE

Abstract:The coronavirus disease (COVID-19) is the global public health challenge currently persisting at a grand scale. A method that meets the rapid quantitative detection of antibodies to assess the body’s immune response from natural COVID-19 illness or vaccines’ effects is urgently needed. In the present study, an attempt was made to integrate a newly designed spectrometer to the COVID-19 test strip procedure; this augmentation provides the quantitative capacity to a lateral flow immunoassay (LFIA). Optical interpretation of results by quantitative α index, rather than visual qualification, can be done quickly, in 5–10 minutes. The developed product was compared with several other serological IgM/IgG antibody reagents on the market by recruiting 111 participants suspected of having COVID-19 infection from March to May 2020 in a hospital. Taking RT-PCR as the diagnostic gold standard, the quantitative spectral LIFA platform could correctly detect all 12 COVID-19 patients. Concerning RT-PCR negative patients, all three antibody testing methods found positive cases. The optical-based platform exhibited the ability of early detection of immunoglobulins of RT-PCR negative patients. There was an apparent trend that elevation of IgM levels in the acute phase of infection; then IgG levels rose later. It exhibited the risk of a false-negative diagnosis of RT-PCR in COVID-19 testing. The significant detection ability of this new optical-based platform demonstrated clinical potential.

multidisciplinary sciences

Proximal tibial valgus osteotomy. The Veterans Administration Hospital experience, Wichita, Kansas, 1977-82.

Assessment of antibody dynamics and neutralizing activity using serological assay after SARS-CoV-2 infection and vaccination

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits

Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies

Evaluation of serum IgM and IgG antibodies in COVID‐19 patients by enzyme linked immunosorbent assay

Antibody titers and the risk of infection during the SARS-CoV-2 Omicron phase in Bizen City, Japan

Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort

Quantitative Detection of Anti-SARS-CoV-2 Antibodies Using Indirect ELISA

Rapid and Low-Cost Detection and Quantification of SARS-CoV-2 Antibody Titers of ICU Patients with Respiratory Deterioration Using a Handheld Thermo-Photonic Device

Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status

Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications

Development of a unit conversion tool for five quantitative anti-spike assays and agreement analysis of three qualitative anti-nucleocapsid assays for SARS-CoV-2

Validation of an interferon-gamma enzyme-linked immunosorbent spot assay to evaluate cell-mediated immunity against severe acute respiratory syndrome coronavirus 2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study

Investigation of Antibody Levels During Three Doses of Sinopharm/BBIBP Vaccine Inoculation

Performance Analysis of Serodiagnostic Tests to Characterize the Incline and Decline of the Individual Humoral Immune Response in COVID-19 Patients: Impact on Diagnostic Management

In-network processing of the GPU-based real-time DXT compression

Exploring Rapid and Effective Screening Methods for Anti-SARS-CoV-2 Neutralizing Antibodies in COVID-19 Convalescent Patients and Longitudinal Vaccinated Populations

Study of the humoral immune response against SARS-CoV-2 post-infectious and post-vaccination

The early detection of immunoglobulins via optical-based lateral flow immunoassay platform in COVID-19 pandemic